Contact Us
Drug Search Results
More Filters [+]

Rinucumab

Alternative Names: rinucumab, REGN2176-3, REGN21763, REGN2176, REGN-2176
Latest Update: 2020-10-26
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: N/A

Novel Mechanism: No

Modality: Antibody

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Regeneron
Company Location: TARRYTOWN NY 10591
Company CEO: Leonard S. Schleifer
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Rinucumab

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Wet Macular Degeneration|Neovascular age-related macular degeneration

Phase 1: Wet Macular Degeneration

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
CAPELLA

P2

Terminated

Wet Macular Degeneration|Neovascular age-related macular degeneration

2016-08-17

R2176-3-AMD-1303

P1

Completed

Wet Macular Degeneration

2014-12-01

Recent News Events

Date

Type

Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions